Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Leukemia, B-Cell

St. Jude Children's Research Hospitalprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Leukemia, B-Cell cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
St. Jude Children's Research Hospital
Phase 2BB
PEGASPARGASE
Children's Oncology Group
Phase 2B
Inno-206
Children's Oncology Group
Phase 2B
Cyclophosphamide
Dana-Farber Cancer Institute
Phase 2B
Solu-Cortef
Children's Oncology Group
Phase 2B

View all 22 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →